MRE Predictors of Disease Relapse After Stopping Biologics - Trial NCT06124287
Access comprehensive clinical trial information for NCT06124287 through Pure Global AI's free database. This phase not specified trial is sponsored by University College, London and is currently Not yet recruiting. The study focuses on Crohn's Disease. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University College, London
Timeline & Enrollment
N/A
Feb 01, 2024
Feb 01, 2027
Primary Outcome
To develop and internally evaluate a multivariable prediction model for early disease relapse in patients stopping biological therapy
Summary
This study aims to investigate if MR Enterography (MRE) improves the ability to predict which
 Crohn's disease patients will relapse quickly (disease comes back) after stopping biologic
 medication. MRE is a safe MRI scan of the bowel, widely used in Crohn's disease patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06124287
Non-Device Trial